Navigation Links
New therapy for childhood neuroblastoma proves feasible and safe
Date:6/29/2011

Reston, Va. (June 29, 2011) A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emission tomography and X-ray computed tomography (PET/CT) may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with a molecular radiotherapy known as 177Lu-DOTATATE. This therapeutic option was found to be viable option for children with neuroblastomas.

Neuroblastoma is a cancerous tumor that develops from nerve tissue in infants and children. Accounting for six to 10 percent of all childhood cancers, it does not always follow the same pattern, with some patients regressing spontaneously and other progressing, despite aggressive therapy. The long-term survival rate for neuroblastoma is below 40 percent.

"We know that peptide receptor radionuclide therapy in adults with somatostatin-positive neuroendocrine tumors has resulted in improved symptoms, prolonged survival and an enhanced quality of life. Since some neuroblastomas express somatostatin receptors, we felt this approach could be beneficial to children as well," said Jamshed B. Bomanji, MBBS, PhD, FRCR, FRCP, one of the authors of the study "177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma."

In the study, eight children with relapsed or primary refractory neuroblastoma were imaged with a 68Ga-DOTATATE PET/CT scan. If the disease sites showed 68Ga-DOTATATE uptake greater than the liver, the child was considered eligible for the molecular radiotherapy. Therapy with 177Lu-DOTATATE was determined to be suitable for six of the children and was administered appropriately.

After completing treatment with 177Lu-DOTATATE, five children had stable disease by the response evaluation criteria in solid tumors. The treatment was feasible, practical and well-tolerated in the small group of patients with high-risk neuroblastoma. As a result, the researchers plan to evaluate 177Lu-DOTATATE formally in a phase I-II clinical trial to evaluate toxicity and response.

"Molecular imaging has contributed a new diagnostic technique to map the full extent of disease. This mode of treatment has great potential for children whose treatment options are limited, as neuroblastoma often becomes resistant to chemotherapy and success is limited by poor bone marrow reserve," noted Bomanji.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Nicotine replacement therapy is over-promoted since most ex-smokers quit unassisted
2. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
3. Longview Therapy Center, PLLC, Unveils Its Definition Of Hope
4. Short-term radiation therapy successful on breast cancer
5. ASCROs Response to NY Times Articles on Radiation Therapy Incidents
6. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
7. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
8. Behavioral therapy improves sleep and lives of patients with pain
9. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
10. Promising therapy for relapsing multibple sclerosis
11. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... With ... is so critically important that we all are aware of our options and ... is proud to announce the launch of its newest edition of "Vision and ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... Pharma To Market Pty Ltd and Ador Consulting Pte Ltd announce ... of Pharma To Market Pte Ltd, based in Singapore ... their expansion into Asia with the opening ... are delighted to appoint Joelle Chia , former owner of ... based entity. Joelle brings with her an extensive business network throughout ...
Breaking Medicine Technology: